A client with an early-stage CD19-targeted cell therapy for DLBCL sought our guidance on how to differentiate their product positioning.
Task
Develop a positioning strategy that leverages the differentiated strengths of this therapy relative to its most-likely competitors at the time of launch.
Action
Characterized the DLBCL treatment landscape and anticipated unmet need.
Sorted emerging therapies according to target patient populations within DLBCL.
Summarized proof-of-concept data to date and identified emerging trends in regards to efficacy, safety and dosing.
Pinpointed weaknesses of cell therapy front-runners in development, such as long-term durability.
Articulated strengths of current front-runners in development, such as ease of manufacturing.
Leveraged primary intelligence to garner firsthand stakeholder perspectives and identify white spaces” for market entry.
Results
The client utilized our insights to supercharge their DLBCL clinical development strategy and identify key areas for product differentiation, focusing on enhancing longevity of response and reducing lymphodepletion.
Utilized insights
Pinpointed unmet need
Supercharged strategy
Defined a Differentiation
Strategy in a Crowded Landscape
No items found.
Please note: images are for illustrative purposes only.
By clicking "Accept cookies", you agree to storing cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts as outlined in our privacy policy.
By clicking 'Accept all cookies', you agree to storing cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts as outlined in our privacy policy.
